Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Jan;15(1):131-143.
doi: 10.1007/s40271-021-00534-y. Epub 2021 Jun 28.

Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals

Sarah-Jane Anderson  1   2 , Miranda Murray  3 , David Cella  4 , Robert Grossberg  5 , Debbie Hagins  6 , William Towner  7 , Marcia Wang  8 , Andrew Clark  3 , Amy Pierce  9 , Cyril Llamoso  10 , Peter Ackerman  10 , Max Lataillade  10
Affiliations
Clinical Trial

Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals

Sarah-Jane Anderson et al. Patient. 2022 Jan.

Abstract

Introduction: Heavily treatment-experienced (HTE) people living with HIV-1 (PLWH) have limited viable antiretroviral regimens available because of multidrug resistance and safety concerns. The first-in-class HIV-1 attachment inhibitor fostemsavir demonstrated efficacy and safety in HTE participants in the ongoing phase III BRIGHTE trial.

Objectives: We describe patient-reported outcomes (PROs) through week 48.

Methods: Eligible participants for whom their current regimen was failing were assigned to the randomized cohort (RC; one to two fully active agents remaining) or the nonrandomized cohort (NRC; no fully active agents remaining). PRO assessments included the EQ-5D-3L, EQ-VAS, and Functional Assessment of HIV Infection (FAHI) instruments.

Results: Both cohorts achieved increases in EQ-5D-3L US- and UK-referenced utility score from baseline at week 24. Mean visual analog scale (VAS) scores in the RC and NRC increased from baseline by 8.7 (95% CI 6.2-11.2) and 5.6 points (95% CI 1.5-9.7) at week 24 and increased from baseline by 9.8 (95% CI 7.0-12.6) and 4.9 points (95% CI 0.6-9.2) at week 48, respectively. Mean increases in FAHI total score from baseline to weeks 24 and 48 in the RC were 6.9 (95% CI 4.2-9.7) and 5.8 (95% CI 2.7-9.0), respectively, whereas mean increases in physical and emotional well-being subscale scores were 2.7 (95% CI 1.9-3.6) and 2.4 (95% CI 1.3-3.4) and 3.2 (95% CI 2.2-4.2) and 2.6 (95% CI 1.6-3.7), respectively, with little to no change in other subscales.

Conclusions: Improvements in major domains of the EQ-VAS and FAHI through week 48, combined with efficacy and safety results, support the use of fostemsavir for HTE PLWH.

Trial registration number and date: NCT02362503; February 13, 2015.

PubMed Disclaimer

Conflict of interest statement

S-JA and MW are employees of and own stock in GlaxoSmithKline. MM was an employee of ViiV Healthcare when the work was conducted, is now with Health Analytics and Outcomes, London, UK, and owns/owned stock in GlaxoSmithKline. DC is president of FACIT.org, which licenses FAHI, and has been a consultant to ViiV Healthcare. RG has received research support from ViiV Healthcare, Amgen, and Gilead Sciences; consulting fees from Thera Technologies as member of an advisory board; and speaker fees from ViiV Healthcare. DH has received speaker fees and consulting fees from ViiV Healthcare as a member of an advisory board. WT is an employee of Southern California Permanente Medical Group and has received institutional grants from ViiV Healthcare, Bristol-Myers Squibb, Gilead, Dynavax, and Merck. AC, AP, CL, PA, and ML are employees of ViiV Healthcare and own stock in GlaxoSmithKline.

Figures

Fig. 1
Fig. 1
BRIGHTE study disposition at week 24 and week 48
See this image and copyright information in PMC

References

    1. Palella FJ Jr, Delaney KM, Moorman AC, et al, and the HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338(13):853–60. - PubMed
    1. Brown J, Chien C, Timmins P, et al. Compartmental absorption modeling and site of absorption studies to determine feasibility of an extended-release formulation of an HIV-1 attachment inhibitor phosphate ester prodrug. J Pharm Sci. 2013;102(6):1742–1751. doi: 10.1002/jps.23476. - DOI - PubMed
    1. Langley DR, Kimura SR, Sivaprakasam P, et al. Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action. Proteins. 2015;83(2):331–350. doi: 10.1002/prot.24726. - DOI - PMC - PubMed
    1. Ray N, Hwang C, Healy MD, et al. Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068. J Acquir Immune Defic Syndr. 2013;64(1):7–15. doi: 10.1097/QAI.0b013e31829726f3. - DOI - PubMed
    1. Nowicka-Sans B, Gong Y-F, McAuliffe B, et al. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. Antimicrob Agents Chemother. 2012;56(7):3498–3507. doi: 10.1128/AAC.00426-12. - DOI - PMC - PubMed

Publication types

Associated data